Repositioning Candidate Details
| Candidate ID: | R0538 |
| Source ID: | DB01598 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Imipenem |
| Synonyms: | (5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Imipenem; Imipenem anhydrous; N-formimidoyl thienamycin; N-formimidoylthienamycin |
| Molecular Formula: | C12H17N3O4S |
| SMILES: | [H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O |
| Structure: |
|
| DrugBank Description: | Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to many beta-lactamases. Similar compounds include , known for having greater activity against Gram negative bacteria, and the newer which exhibits a longer half-life due to increased binding to plasma proteins. Imipenem is commonly used in combination with and is now available in a triple-drug product with cilastatin and which was recently approved by the FDA. Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co. |
| CAS Number: | 64221-86-9 |
| Molecular Weight: | 299.346 |
| DrugBank Indication: | Imipenem is indicated, in combination with with or without , for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis. |
| DrugBank Pharmacology: | Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem is active against aerobic and anaerobic Gram positive as well as Gram negative bacteria including <i>Pseudomonas aeruginosa</i> and the <i>Enterococcus</i>. It exerts a bactericidal effects by disrupting cell wall synthesis. |
| DrugBank MoA: | Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria. This inhibition of cell wall synthesis in gram-negative bateria is attained by binding to penicillin-binding proteins (PBPs). In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b. This inhibition of PBPs prevents the bacterial cell from adding to the peptidoglycan polymer which forms the bacterial cell wall eventually leading to cell death. |
| Targets: | Penicillin-binding protein 2 inhibitor; Penicillin-binding protein 1B inhibitor; Penicillin-binding protein 1A inhibitor; Penicillin-binding protein 3 inhibitor; Penicillin-binding protein 4 |
| Inclusion Criteria: | Indication associated |
